Skip to main content

Table 2 Comparison of RCTs accessing RCHD with trials evaluated by the HRA in 2015

From: Access to routinely collected health data for clinical trials – review of successful data requests to UK registries

 RCTs accessing RCHD
(n = 160)
HRA in 2015a
(n = 963b)
Recruitment setting
 Primary care41 (26%)48 (5%)
 Secondary care119 (74%)846 (95%)
 Unclear/missing069
Therapeutic area
 Cancer47 (29%)168 (17%)
 Cardiovascular and stroke46 (29%)121 (13%)
 Pregnancy and childbirth9 (6%)30 (3%)
 Infection8 (5%)55 (6%)
 Inflammatory disorder5 (3%)72 (7%)
Drug trial76 (48%)515 (53%)
Randomisation
 Individual136 (85%)934 (97%)
 Cluster trial24 (15%)29 (3%)
Feasibility/pilot17 (11%)177 (18%)
Sample size (median, range)1590 (41–6,000,000)275 (6–30,000)
 Unclear/missing0440
Recruitment location
 UK only125 (78%)450 (50%)
 International trials32 (20%)443 (50%)
 Unclear/missing070
  1. This table only includes data fields that were comparable between the two sources. Sample size targets in the UK Health Research Authority (HRA) cohort are limited to those not described as phase I/II trials. Data obtained from Clark et al. [11] (2018), including unpublished supplementary appendices [1]. Abbreviations: RCHD routinely collected health data, RCT randomised controlled trial
  2. aClark et al. [11].
  3. bFor recruitment setting and location, the unclear/missing values were omitted from the percentage calculation.